Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study

Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin‐2, a hormone with vasodilatory and end‐organ protective effects believed to play a central role in the car...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Eur J Heart Fail
Huvudupphovsmän: Teerlink, John R., Voors, Adriaan A., Ponikowski, Piotr, Pang, Peter S., Greenberg, Barry H., Filippatos, Gerasimos, Felker, G. Michael, Davison, Beth A., Cotter, Gad, Gimpelewicz, Claudio, Boer‐Martins, Leandro, Wernsing, Margaret, Hua, Tsushung A., Severin, Thomas, Metra, Marco
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Ltd 2017
Ämnen:
Trial Design
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5488179/
https://ncbi.nlm.nih.gov/pubmed/28452195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.830
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk